HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA)

HC Wainwright reissued their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a report released on Friday,Benzinga reports. HC Wainwright currently has a $23.00 target price on the stock.

Separately, Oppenheimer dropped their price target on shares of Protara Therapeutics from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th.

Protara Therapeutics Trading Down 1.8 %

Shares of NASDAQ:TARA opened at $5.91 on Friday. The company’s 50-day moving average price is $2.35 and its 200 day moving average price is $2.27. Protara Therapeutics has a fifty-two week low of $1.37 and a fifty-two week high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). As a group, research analysts forecast that Protara Therapeutics will post -2.99 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Opaleye Management Inc. sold 32,600 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $1.71, for a total value of $55,746.00. Following the sale, the insider now directly owns 51,500 shares in the company, valued at $88,065. The trade was a 38.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.50% of the stock is owned by insiders.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TARA. XTX Topco Ltd bought a new stake in shares of Protara Therapeutics in the 3rd quarter worth approximately $60,000. Marshall Wace LLP purchased a new position in shares of Protara Therapeutics in the second quarter worth approximately $161,000. Geode Capital Management LLC increased its position in shares of Protara Therapeutics by 21.0% in the third quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after acquiring an additional 29,514 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Protara Therapeutics by 77.8% in the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after acquiring an additional 65,800 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of Protara Therapeutics by 40.8% in the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock worth $328,000 after acquiring an additional 51,944 shares in the last quarter. 38.13% of the stock is currently owned by institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.